CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas

Lee, Ok-Jun; Son, Seung-Myoung; Hong, Kwon Pyo; Lee, Young Moo; Kim, Minyoung; Choi, Jee Woong; Lee, Sang-Jeon; Song, Young‐Jin; Kim, Hak Soon; Kim, Wun-Jae; Shin, See‐Ok; Song, Hyung Geun

doi:10.1007/s00428-014-1688-1

Cited by 10 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CEACAM6 is a member of the CEA family. Abnormal overexpression of CEACAM6 plays a role in several characteristics of cancer, including uncontrolled proliferation, anoikis resistance, neovascularization, immune avoidance, invasion, and metastasis ( Johnson and Mahadevan, 2015 ; Lee et al, 2015 ; Rizeq et al, 2018 ). MYB has now been investigated as an oncogene that is involved in some human leukemias.…”

Section: Discussionmentioning

confidence: 99%

Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

et al. 2021

View full text Add to dashboard Cite

Bladder cancer is one of the most common urogenital malignancies in the world, and there are no adequate prognostic indicators. CNTD2 is one of the atypical cyclins, which may be related to the cell cycle and even the development of cancers. Early studies have shown that CNTD2 is closely related to the occurrence and development of many malignant tumors. However, the mechanism of CNTD2 in bladder cancer has not been reported. In our research, we explored the different expressions of CNTD2 between 411 bladder cancers and 19 normal bladder tissues based on the TCGA dataset. CNTD2-related signaling pathways were identified through the GSEA. We analyzed the associations of CNTD2 expression and bladder cancer progression and survival using GSE13507. Compared with 19 cases of normal bladder tissue, CNTD2 gene expression was increased in 411 cases of bladder cancer. The high expression of CNTD2 strongly correlated with grade (P < 0.0001), T classification (P = 0.0001), N classification (P = 0.00011), M classification (P = 0.044), age (P = 0.027), and gender (P = 0.0012). Bladder cancer patients with high CNTD2 expression had shorter overall survival (P < 0.001). In the meantime, univariate and multivariate analyses showed that the increased expression of CNTD2 was an independent factor for poor prognosis in bladder cancer patients (P < 0.001 and P < 0.001, respectively). CNTD2 expression is closely related to bladder cancer progression, and the high expression of CNTD2 may be an adverse biomarker in bladder cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nonspecific cross-reacting antigen (NCA-90, CEACAM6), a member of the carcinoembryonic antigen gene family, is expressed on granulocytes and epithelial tissue [ 67 ]. It is a complex cell-surface glycoprotein macromolecule that is involved in cell adhesion and tumour progression, implicated particularly in the context of cytokine-activated neutrophil-endothelial cell adhesion [ 67 ]. In the absence of adhesive interactions with the extracellular matrix, normal cells undergo anoikis.…”

Section: Potential Theranostic Targets In Mocmentioning

confidence: 99%

The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic

Youssef

Haskali

Gorringe

2021

Cancers

View full text Add to dashboard Cite

MOC is a rare histotype of epithelial ovarian cancer, and current management options are inadequate for the treatment of late stage or recurrent disease. A shift towards personalised medicines in ovarian cancer is being observed, with trials targeting specific molecular pathways, however, MOC lags due to its rarity. Theranostics is a rapidly evolving category of personalised medicine, encompassing both a diagnostic and therapeutic approach by recognising targets that are expressed highly in tumour tissue in order to deliver a therapeutic payload. The present review evaluates the protein landscape of MOC in recent immunohistochemical- and proteomic-based research, aiming to identify potential candidates for theranostic application. Fourteen proteins were selected based on cell membrane localisation: HER2, EGFR, FOLR1, RAC1, GPR158, CEACAM6, MUC16, PD-L1, NHE1, CEACAM5, MUC1, ACE2, GP2, and PTPRH. Optimal proteins to target using theranostic agents must exhibit high membrane expression on cancerous tissue with low expression on healthy tissue to afford improved disease outcomes with minimal off-target effects and toxicities. We provide guidelines to consider in the selection of a theranostic target for MOC and suggest future directions in evaluating the results of this review.

show abstract

“…This result suggests that TOBi85 and TOBi89 bind to distinct CEACAM6 epitopes, and that these epitopes may be differentially expressed in SUIT2 cells. Indeed, CEACAM6 is known to be heavily glycosylated, and antigenic variants of this glycoprotein have been previously described [20][21][22][23].…”

Section: Identification Of the Cognate Antigens Of The Tobi-bodiesmentioning

confidence: 99%

Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models

Oni

Bautista

Merrill

et al. 2020

Preprint

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, as 90% of patients do not survive beyond five years from diagnosis. This dismal prognosis is largely due to the advanced stage of the disease at diagnosis, which precludes potentially curative surgical resection. Although early detection strategies hold significant promise for improving patient outcomes, there is still no accurate diagnostic tool to detect incipient PDAC. Here, we sought to develop antibodies for the early detection of PDAC by positron-emission tomography (PET) imaging. Accordingly, we establish a pipeline to generate novel tumor-specific monoclonal antibodies (mAbs) against cell-surface proteins of PDAC patient-derived organoids (PDOs). We identify a panel of 16 tumor organoid-binding antibodies (TOBi-bodies) that display high reactivity to human PDAC tissues but not to matched adjacent normal pancreas. We then employ biochemical, flow cytometric, mass spectrometric, and CRISPR/Cas9-mediated knockout methods to determine the cognate antigens of these TOBi-bodies. We identify two mAbs that bind to tumor-specific variants of the surface protein CEACAM6 and show minimal binding to normal tissues. PET imaging in mouse models using these TOBi-bodies enables the detection of incipient human organoid-derived PDAC tumors that are rather undetectable by palpation or high-resolution ultrasound imaging techniques. We propose that further development of these mAbs as PET radiotracers could facilitate the early detection and accurate staging of PDAC.

show abstract

CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas

Cited by 10 publications

References 38 publications

Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507

The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic

Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models

Contact Info

Product

Resources

About